The publication of the Cochrane review into the use of neuraminidase inhibitors on April 10 underlined the concerns raised in the Jan 3 UK House of Commons Committee of Public Accounts report on the stockpiling of oseltamivir by the UK Government. The committee's concerns centred on their discovery that clinical trial data for treatments prescribed in the UK are routinely withheld from doctors and researchers. They also acknowledged that this problem is not new and has been recognised in academic circles for many years. The committee concluded that the government should take action to ensure data for all trials are made available and that there should be an audit of unpublished trial data.
展开▼
